Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: Current antibiotic prescription for acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is generally based on the Anthonisen criteria in The Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) guideline that have a potential risk of antibiotics overuse. The dilemma is to identify patients who are most likely to benefit from antibiotics while avoiding unnecessary antibiotic use. Procalcitonin (PCT), a more sensitive and specific biomarker of bacterial infection than other conventional laboratory tests, has the potential to determine those patients in whom antibiotics would be beneficial. It is unclear whether PCT-guided antibiotic therapy is safe and effective for patients hospitalised with AECOPD. The study hypothesis is that PCT-guided antibiotic therapy could reduce the antibiotic prescription rate for AECOPD, compared with the GOLD guideline recommendations, without negatively impacting the treatment success rate.
Methods And Analysis: In this multicenter, open-label, randomised controlled trial, we aim to enrol 500 hospitalised patients with AECOPD that will be randomly assigned to either a PCT-guided group or a GOLD guideline-guided group. The coprimary endpoints are antibiotic prescription rate for AECOPD within 30 days post randomisation and treatment success rate at day 30 post randomisation. The secondary outcomes include: antibiotic prescription rate at day 1 post randomisation; hospital antibiotic exposure; length of hospital stay; rate of subsequent exacerbation and hospital readmission; overall mortality within 30 days post randomisation; changes in lung function and the score of COPD assessment test and modified Medical Research Council; and rate of intensive care unit admission.
Ethics And Dissemination: This trial has been approved by the ethic committee of China-Japan Friendship Hospital. The findings of the study will be disseminated in peer-reviewed journals. If the results of the study are positive, PCT-guided antibiotic therapy is likely to change the guidelines for antibiotic recommendations for patients with AECOPD.
Trial Registration Number: ClinicalTrials.gov: NCT04682899.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8344287 | PMC |
| http://dx.doi.org/10.1136/bmjopen-2021-049515 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Shenling Jianpiwei formula ameliorates metabolic associated fatty liver disease through modulation of the gut microbiota and attenuation of LPS-mediated inflammation.
Fitoterapia
September 2025
Yunnan Key Laboratory of Southern Medicine Utilization, College of Traditional Chinese Medicine, Yunnan University of Chinese Medicine, Kunming 650500, China. Electronic address:
The gut microbiota and its products are recognized as pivotal contributors to the pathogenesis of metabolic-associated fatty liver disease (MAFLD). Shenling Jianpiwei formula (SLJPW), a prescription renowned for its protective effects in intestinal disorders, demonstrates efficacy against MAFLD. However, its underlying mechanisms and chemical composition remain unclear.
View Article and Find Full Text PDFInvestigating the know-do gap in antibiotics prescribing: Experimental evidence from India.
Sci Adv
September 2025
Sol Price School of Public Policy, University of Southern California, Los Angeles, CA, USA.
Antimicrobial resistance is largely driven by overuse of antibiotics, which is particularly common in low- and middle-income countries. We combine provider knowledge assessments and over 2000 anonymous standardized patient visits to providers in India to examine why they overprescribe antibiotics for pediatric diarrhea and figure out how to reduce overprescribing. Seventy percent of providers prescribed antibiotics without indication of bacterial infection.
View Article and Find Full Text PDFConcomitant Comedications and Survival With First-Line Pembrolizumab in Advanced Non-Small-Cell Lung Cancer.
JAMA Netw Open
September 2025
Oncostat U1018, Institut National de la Santé et de la Recherche Médicale (INSERM), Ligue Contre le Cancer, Paris-Saclay University, Villejuif, France.
Importance: Antibiotics, steroids, and proton pump inhibitors (PPIs) are suspected to decrease the efficacy of immunotherapy.
Objective: To explore the association of comedications with overall survival (OS) in patients with advanced non-small-cell lung cancer (NSCLC).
Design, Setting, And Participants: This nationwide retrospective cohort study used target trial emulations of patients newly diagnosed with NSCLC from January 2015 to December 2022, identified from the French national health care database.
Barriers and facilitators to infection prevention and control practices at King Faisal Hospital, Kigali, Rwanda.
Antimicrob Steward Healthc Epidemiol
September 2025
Infectious Disease, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Objective: To identify barriers and facilitators of infection prevention and control (IPC) practices at King Faisal Hospital (KFH) in Kigali, Rwanda, using the Systems Engineering Initiative for Patient Safety (SEIPS) model.
Design: Qualitative study involving semi-structured interviews.
Setting: King Faisal Hospital, a tertiary healthcare facility in Kigali, Rwanda.
infection and antibiotic prescribing at a regional hospital in Australia: a case-control study.
Antimicrob Steward Healthc Epidemiol
September 2025
National Centre for Epidemiology and Population Health, Australian National University, Canberra, ACT, Australia.
Background: infections (CDI) increased at a large, regional hospital in New South Wales, Australia, in 2021, coinciding with an increase at hospitals Australia wide. We aimed to investigate the association between antibiotic prescribing practices and hospital-acquired CDI at the hospital to inform antimicrobial stewardship (AMS) programs.
Methods: We conducted a retrospective case-control study for the period July 1, 2018, and June 30, 2022.